The Cooper Companies, Inc. (NASDAQ:COO) Shares Acquired by Sumitomo Life Insurance Co.

Sumitomo Life Insurance Co. boosted its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 3.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 11,106 shares of the medical device company’s stock after acquiring an additional 328 shares during the quarter. Sumitomo Life Insurance Co.’s holdings in Cooper Companies were worth $1,225,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Cooper Companies by 248.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock worth $25,000 after acquiring an additional 174 shares during the last quarter. Covestor Ltd boosted its stake in Cooper Companies by 305.9% during the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after purchasing an additional 208 shares during the last quarter. Innealta Capital LLC purchased a new stake in shares of Cooper Companies during the second quarter worth $25,000. Crewe Advisors LLC raised its position in shares of Cooper Companies by 286.4% in the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after buying an additional 252 shares during the last quarter. Finally, Clearstead Trust LLC purchased a new position in shares of Cooper Companies in the first quarter worth about $36,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on COO shares. Jefferies Financial Group raised shares of Cooper Companies from a “hold” rating to a “buy” rating and raised their target price for the stock from $107.00 to $115.00 in a research note on Tuesday, July 16th. Wells Fargo & Company lifted their price objective on Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Stifel Nicolaus restated a “buy” rating and issued a $115.00 target price (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Robert W. Baird lifted their price target on Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, August 29th. Finally, Piper Sandler upped their price objective on shares of Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $115.00.

Cooper Companies Trading Up 0.0 %

Shares of NASDAQ COO opened at $108.56 on Thursday. The stock has a fifty day simple moving average of $103.71 and a 200-day simple moving average of $96.31. The Cooper Companies, Inc. has a twelve month low of $75.93 and a twelve month high of $112.38. The company has a current ratio of 1.99, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $21.62 billion, a PE ratio of 63.86, a PEG ratio of 2.56 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.05. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.84 earnings per share. On average, equities analysts forecast that The Cooper Companies, Inc. will post 3.65 earnings per share for the current year.

Insider Transactions at Cooper Companies

In related news, COO Daniel G. Mcbride sold 114,992 shares of Cooper Companies stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the completion of the transaction, the chief operating officer now directly owns 44,696 shares in the company, valued at approximately $4,714,534.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, COO Daniel G. Mcbride sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total value of $12,129,356.16. Following the completion of the transaction, the chief operating officer now owns 44,696 shares in the company, valued at $4,714,534.08. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Brian G. Andrews sold 24,788 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the transaction, the chief financial officer now owns 6,614 shares of the company’s stock, valued at $700,422.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is currently owned by company insiders.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.